期刊
CLINICAL CANCER RESEARCH
卷 18, 期 2, 页码 577-584出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-1387
关键词
-
类别
资金
- Roch/Genentech
- Cancer and Leukemia Group B
- CALGB Statistical Center [CA33601]
- Ministry of Education, Culture, Sports, Science and Technology of the Japanese government [K07-CA140390-01, T32 MH200065-06, 5K24-CA113755, CA60138, U01 GM61393]
- NIH Pharmacogenomics Research Network (PGRN)-RIKEN Center for Genomic Medicine (CGM) Strategic Alliance
Background and Aims: Cancer and Leukemia Group B 80303 was a randomized, phase III study in patients with advanced pancreatic cancer treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected germline DNA and conducted a genome-wide association study (GWAS) using overall survival (OS) as the endpoint. Experimental Design: DNA from 351 patients was genotyped for more than 550,000 single-nucleotide polymorphisms (SNP). Associations between OS and SNPs were investigated using the log-linear 2-way multiplicative Cox proportional hazards model. The subset of 294 genetically European patients was used for the primary analysis. Results: A nonsynonymous SNPin interleukin (IL) 17F (rs763780, H161R) and an intronicSNP in strong linkage disequilibrium (rs7771466) were associated with OS using genome-wide criteria (P <= 10(-7)). Median OS was significantly shorter (P = 2.61 x 10(-8)) for the rs763780 heterozygotes [3.1 months; 95% confidence interval (CI), 2.3-4.3] than for the patients without this variant (6.8 months; 95% CI, 5.8-7.3). After adjustment by stratification factors, the P value for the association was 9.51 x 10(-7). Conclusions: The variant 161R form of IL-17F is a natural antagonist of the antiangiogenic effects of wild-type 161H IL-17F, and angiogenesis may play an important role in the metastatic spread of pancreatic cancer. In this preliminary study, we hypothesize that the angiogenetic potential of pancreatic cancers in patients with variant IL-17F is higher than that of tumors in patients with wild-type IL-17F, conferring worse prognosis. This exploratory GWAS may provide the foundation for testing the biology and clinical effects of novel genes and their heritable variants through mechanistic and confirmatory studies in pancreatic cancer. Clin Cancer Res; 18(2); 577-84. (C) 2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据